@Hobnobs
Misconception, the drug no longer has a patent, the company acquired the generic drug rights.
Those with toxoplasmosis number in the thousand. It's a rare infection actually. It's not HIV nor an AIDS drug, it's for the rare parasitic infection itself. Because of that, it's not a very profitable margin when relying on the thousands range to get 100 pills of a drug. That's why it's understandable to not have the drug being made and phased out as a matter of production possibility frontier when manufacturing other drugs with the time and resources be the better alternative especially in face of investors and alike who expect productivity and profits.
Moreover, the $750 is mostly a price tag. There's was a patient assistance program that helps the uninsured get the drug for free if you are a legal resident and 500% below the poverty line. Couple that with the lowered co-pay amount negotiation by like $10 or so with insurance, there shouldn't be much problem. Instances of not getting the drug would typically involve lack of communication. The man and the company (name probably now changed) did have a pipeline with TRP-004 (aka the newer improved drug whose name also probably changed with the company) in the works. Before, you had to take it alongside folinic acid to protect the bone marrow. With the new drug hopefully in the works, it would have eliminated the need and the old drug side effects. And there is a matter of filling out info and such but it's hardly a matter let alone no incident really reported. If you're an illegal alien, it is an entirely different story.
Martin never spoke in great detail but he liked to act like a huge shitposter which you guessed caused him alot of trouble.
And mind you, if you argue on the basis of premiums increasing, it's mostly due to inpatient and outpatient spending. Prescription drugs only account for small percentage of the issue and Daraprim, the drug in question, hardly accounts for the problem.
